Portfolio Companies

Lund, Sverige, 10.00 CET, 8 July 2021 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, will publish its Interim Re...
Read more

STOCKHOLM — July 8, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematologic...
Read more

• Experienced Industry Leader with successful Oncology, Immunotherapy & ADC Development Track Record Copenhagen, Denmark, 7 July 2021 – Adcendo, a biotech company devel...
Read more

Oslo, Norway, 1 July 2021 – Targovax ASA (OSE: TRVX) announces the appointment of Dr Lone Ottesen, MD, PhD as Chief Development Officer (CDO). She will take a lea...
Read more

Oslo, Norway, 1 July 2021 Nordic Nanovector ASA (OSE: NANOV) announces that Ms. Malene Brondberg has been appointed interim Chief Executive Officer with immediate effect. Ms...
Read more

Dr. Ways’ Expertise in Late-Stage Clinical Development in Therapeutics Areas of High Unmet Medical Meet Supports Spruce’s Goal to Expand Portfolio of Indications for...
Read more

Single Pivotal Phase 3 Trial in Atrial Fibrillation Acceptable to Support Filing of New Drug Application Company on Track to Initiate Phase 3 RESTORE1 Study in Q3 2021 with Dat...
Read more

Oslo, Norway, 22 June 2021 Nordic Nanovector ASA (OSE: NANOV) announces encouraging initial results from the LYMRIT 37-05 Phase 1 trial investigating Betalutin® (177Lu lilotom...
Read more

The US FDA grants ONCOS-102 Fast Track designation for PD-1-refractory advanced melanomaFast Track designation further strengthens the opportunity for accelerated approval for ONC...
Read more

Tildacerfont was Evaluated in Two Phase 2 Open-Label Studies in Adults with Classic Congenital Adrenal Hyperplasia (CAH) Data Demonstrated Normalization or Trend to Normalizati...
Read more